Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  239.30
-2.43 (-1.01%)
AAPL  259.48
+1.20 (0.46%)
AMD  236.73
-15.45 (-6.13%)
BAC  53.20
+0.12 (0.23%)
GOOG  338.53
-0.13 (-0.04%)
META  716.50
-21.81 (-2.95%)
MSFT  430.29
-3.21 (-0.74%)
NVDA  191.13
-1.38 (-0.72%)
ORCL  164.58
-4.43 (-2.62%)
TSLA  430.41
+13.85 (3.32%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.